Golden State Equity Partners Grows Holdings in Johnson & Johnson $JNJ

Golden State Equity Partners raised its position in Johnson & Johnson (NYSE:JNJ) by 20.5% in the third quarter, HoldingsChannel.com reports. The institutional investor owned 21,491 shares of the company’s stock after purchasing an additional 3,654 shares during the period. Johnson & Johnson makes up approximately 0.7% of Golden State Equity Partners’ investment portfolio, making the stock its 26th biggest position. Golden State Equity Partners’ holdings in Johnson & Johnson were worth $3,985,000 at the end of the most recent quarter.

Other institutional investors have also modified their holdings of the company. Clayton Financial Group LLC purchased a new stake in Johnson & Johnson during the 3rd quarter worth approximately $28,000. Evolution Wealth Management Inc. acquired a new stake in shares of Johnson & Johnson during the second quarter worth approximately $27,000. Semmax Financial Advisors Inc. increased its stake in shares of Johnson & Johnson by 55.0% in the second quarter. Semmax Financial Advisors Inc. now owns 203 shares of the company’s stock worth $31,000 after buying an additional 72 shares during the last quarter. GFG Capital LLC acquired a new stake in Johnson & Johnson in the second quarter valued at $35,000. Finally, Signature Resources Capital Management LLC raised its holdings in Johnson & Johnson by 262.9% in the third quarter. Signature Resources Capital Management LLC now owns 254 shares of the company’s stock valued at $47,000 after acquiring an additional 184 shares in the last quarter. Institutional investors and hedge funds own 69.55% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on JNJ shares. Johnson Rice set a $190.00 target price on shares of Johnson & Johnson and gave the stock a “hold” rating in a research report on Wednesday, October 22nd. Sanford C. Bernstein lifted their price target on Johnson & Johnson from $172.00 to $193.00 and gave the stock a “market perform” rating in a research note on Monday, October 6th. JPMorgan Chase & Co. boosted their price objective on Johnson & Johnson from $185.00 to $200.00 and gave the company a “neutral” rating in a report on Tuesday, September 16th. Guggenheim increased their target price on Johnson & Johnson from $206.00 to $227.00 and gave the stock a “buy” rating in a report on Friday, December 5th. Finally, Bank of America lifted their target price on Johnson & Johnson from $204.00 to $220.00 and gave the stock a “neutral” rating in a research report on Monday, December 15th. Four analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and nine have issued a Hold rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $211.25.

Johnson & Johnson Stock Up 0.1%

NYSE:JNJ opened at $207.26 on Monday. The company has a current ratio of 1.07, a quick ratio of 0.80 and a debt-to-equity ratio of 0.50. The stock has a 50 day moving average of $201.17 and a 200-day moving average of $183.07. The firm has a market capitalization of $499.35 billion, a PE ratio of 20.01, a price-to-earnings-growth ratio of 2.13 and a beta of 0.34. Johnson & Johnson has a 52 week low of $140.68 and a 52 week high of $215.18.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Wednesday, August 30th. The company reported $2.26 earnings per share (EPS) for the quarter. Johnson & Johnson had a return on equity of 32.73% and a net margin of 27.26%.The business had revenue of $24.02 billion during the quarter. Analysts predict that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 10th. Investors of record on Tuesday, February 24th will be issued a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a dividend yield of 2.5%. The ex-dividend date of this dividend is Tuesday, February 24th. Johnson & Johnson’s dividend payout ratio (DPR) is 50.19%.

Johnson & Johnson Company Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.